Delivery Order SPE2DB22D3016-SPE2DB26FAAN4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 50 mg capsules (100 count units) with a ceiling value of $1,441.35. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and represents a non-competitive, non-set-aside award. The contract is performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a ceiling value of $1,100.64. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 19, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply transaction under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,035.18. This firm fixed-price delivery order is set to be completed by October 17, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $1,658.76 to AmerisourceBergen Drug Corp for the supply of Vyvanse capsules (30 mg) on August 20, 2025. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation, leveraging...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a ceiling value of $2,761.55 and an ultimate completion date of September 29, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 13, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a contract value of $1,337.70. This non-set-aside, competitively awarded delivery order carries a firm fixed price structure and is scheduled for completion by September 15, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Vyvanse 30 mg capsules (quantity 100) with a contract value of $1,163.08. This is a firm fixed price delivery order with an ultimate completion date of July 16, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $5,486.46. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to this major pharmaceutical distributor. The order is set for ultimate completion on August 8, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAN4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Vyvanse 50 mg capsules (100 count) with a ceiling value of $1,409.48. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement. The order is scheduled for completion by October 27, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare procurement. The company's DLA IDC represents a comprehensive global pharmaceutical support vehicle enabling the supply of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. Vyvanse, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder, represents one of the diverse pharmaceutical products the contractor delivers under this master contract vehicle to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 10/24/25 |